Further, Biopure has the patents and FDA approval to forge ahead in the animal market with a two-to-five year time buffer from new competition using similar technology. But if the FDA does not approve Hemopure, which could have the potential to cripple a single product biopharmaceutical company, the company may still withstand such a disruption with Oxyglobin sales and future research and development. Another weakness is the uncertainty of market acceptance for Hemopure, in the face of a deeply-rooted blood donation network. Biopure has the potential to lead the market with blood substitutes for human and animal use.
The use of Oxyglobin has shown the following common side effects: Adverse events such as vomiting and melena dark color feces can also occur. Dogs with impaired cardiac function and other conditions that are prediposed to circulatory overload can have adverse events after Oxyglobin administration.
Repeat administration requires careful monitoring. Product strategy[ edit ] For Hemopure, Biopure took a long time to establish which medical indication upon which to focus the majority of its attention. This can be seen through its filings with the U. In contrast, its Oxyglobin product enjoyed a fairly steady strategy, as Biopure consistently marketed the product mostly to small animal veterinarians.
Unfortunately the small market size made turning a profit, especially ex-US, difficult. With the IPO of stock inBiopure was prepared to revolutionize the oxygen therapeutic industry with Hemopure. The company was ready to scale up manufacturing with the impending approval of Hemopure.
In Decemberthe company was also looking to add a large scale manufacturing facility that would produceHemopure units a year Biopure K. Majority of the employees of the company were in the manufacturing department and was one of the biggest costs to the company.
Bythe company had to reduce the workforce to cut cost Biopure oxyglobin launch Hemopure status was in a standstill in Phase III. Number of Employees at Biopure YoY  Biopure was forced into a position to continue raising money to fund the clinical trials in a variety of indications in hopes of getting Hemopure onto the market.
Many of the clinical trials results were being revealed and in Aprilthe FDA put on a hold of a proposed clinical trial on Hemopure for the use in trauma patients in the hospital setting.
The company did not disclose that their clinical trial was on hold to the public and tried to go for an in-hospital trauma trial designation as a separate investigational new drug application INDA from the pending biologic license application BLA for orthopedic surgery indication.
In Julythe FDA did not approve Hemopure for orthopedic surgery and had major concerns about the materials submitted to support the BLA and safety issues.
The charge was violating Section 17 a of the Securities Act of and Section 10 b of the Securities Exchange Act of "Exchange Act" and Rule 10b-5 thereunder and with directly or indirectly violating Section 13 a of the Exchange Act and Rules 12b, 13a-1, 13a and 13a thereunder, and charges Moore with violating Rule 13a thereunder.
The Commission is seeking injunctive relief, civil penalties, and an order barring Moore, Richman and Kober from serving as officers or directors of any public company. The FDA received data from individual studies that demonstrated increasing risk and should have led to terminations of trials.
The current rule is that the agency has the right to keep the information of new products confidential for competitive reasons. Biopure refutes these findings and has been active in defending their position.
The patent is for the use of reducing the toxicity of blood substitute and the NIH has been looking to license the technology.
Peers of Natanson still believe that his study was valid and went through a rigorous process. The judge stopped litigation by the end of A new indictment was charged for lying and if convicted faces 10 years in jail.
District Court and admitted he had instructed his lawyers to tell a judge he was gravely ill with colon cancer.
He also admitted to posing as his doctor in a phone call with his lawyer so that she would tell the judge that his cancer had spread and that he was undergoing chemotherapy. Richman faces up to 10 years in prison at sentencing, scheduled for June There is no plea agreement.
In the first quarter ofit sold "substantially all of its inventory of Oxyglobin to distributors". Biopure "expects to cease operations and sell the Company or its assets" by July 31, For Oxyglobin, potential customers include primary care and emergency care veterinarian service providers.
The conservative market potential for Oxyglobin is M units/year, which translates (assuming a $ /unit price) into /5(1). study how each alternative could help Biopure to stand out from the competitors understand and explain the costs and benefits of each alternative to find out the most profitable alternative Oxyglobin was the first ever blood substitute approved to market and the only blood substitute currently in veterinary market.
Biopure has the potential to lead the market with blood substitutes for human and animal use. With Hemopure on the fringe of FDA approval, one of the largest challenges for Biopure is deciding how Oxyglobin will affect the launch of Hemopure/5(1).
* Biopure has been investing in R&D in the past years without actual revenue generation, the immediate launch of Oxyglobin will allow the company to essentially generate revenue to support the financial activities in the company.
The main problem Biopure faced was whether to launch Oxyglobin now, or wait until Hemopure was approved and launch both products simultaneously.
This was a complex problem as the early launch of Oxyglobin would have both positive and negative repercussions for Biopure. Biopure has the potential to lead the market with blood substitutes for human and animal use.
With Hemopure on the fringe of FDA approval, one of the largest challenges for Biopure is deciding how Oxyglobin will affect the launch of Hemopure.4/4(1).